{
    "nctId": "NCT02441972",
    "briefTitle": "Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics",
    "officialTitle": "Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics",
    "overallStatus": "UNKNOWN",
    "conditions": "Tumors, Carcinoma, Bronchogenic, Breast Carcinoma, Cancer of Head and Neck, Lymphoma, Malignant, Soft Tissue Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Safety data included vital signs (blood pressure, respiratory rate, heart rate, and body temperature) (composite)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Volunteers or patients with age more than 18 yeas;\n2. The patients have been diagnosed with cancer or suspected with cancer;\n3. It must fulfill the ethical requirements and subjects have signed an informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy or nursing mothers;\n2. Having drugs or alcohol dependence;\n3. Hypersensitive to the active or inactive ingredients of the study drug;\n4. Having attended other drug clinical trials within three months;\n5. Cardiac functional insufficiency;\n6. Hepatic and renal function insufficiency;\n7. Hypertensive patients with serious complications;\n8. Endangering the safety of life.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}